The All of Us Research Program: data quality, utility, and diversity

Andrea H. Ramirez*^{1,2}, Lina Sulieman², David J. Schlueter², Alese Halvorson², Jun Qian², Francis

Ratsimbazafy³, Roxana Loperena³, Kelsey Mayo³, Melissa Basford³, Nicole Deflaux⁴, Karthik N. Muthuraman⁴,

Karthik Natarajan⁵, Abel Kho⁶, Hua Xu⁷, Consuelo Wilkins¹, Hoda Anton-Culver⁸, Eric Boerwinkle⁹, Mine Cicek¹⁰,

Cheryl R.Clark¹¹, Elizabeth Cohn¹², Lucila Ohno-Machado¹³, Sheri Schully¹⁴, Brian K. Ahmedani¹⁵, Maria Argos¹⁶,

Robert M. Cronin², Christopher O'Donnell¹⁷, Mona Fouad¹⁸, David B.Goldstein¹⁹, Philip Greenland²⁰, Scott J.

Hebbring²¹, Elizabeth W. Karlson¹¹, Parinda Khatri²², Bruce Korf²³, Jordan W. Smoller²⁴, Stephen Sodeke²⁵, John

Wilbanks²⁶, Justin Hentges¹⁴, Christopher Lunt¹⁴, Stephanie A. Devaney¹⁴, Kelly Gebo¹⁴, Joshua C Denny¹⁴, Robert J.

Carroll², David Glazer⁴, Paul A. Harris², George Hripcsak⁵, Anthony Philippakis²⁷, Dan M. Roden^{1,2,28}, and On behalf of

the All of Us Research Program

¹Departments of Medicine, Vanderbilt University Medical Center; ²Department of Biomedical Informatics, Vanderbilt University Medical Center; ³Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center; ⁴Verily Life Sciences; ⁵Department of Biomedical Informatics, Columbia University Medical Center; ⁶Center for Health Information Partnerships, Northwestern University; ⁷School of Biomedical Informatics, The University of Texas Health Science Center at Houston; ⁸Department of Medicine, University of California Irvine; ⁹School of Public Health, The University of Texas Health Science Center at Houston; ¹⁰Department of Laboratory Medicine and Pathology, Mayo Clinic; ¹¹Department of Medicine, Brigham and Women's Hospital; ¹²Hunter-Bellevue School of Nursing, Hunter College City University of New York; ¹³Department of Biomedical Informatics, UCSD Health; ¹⁴All of Us Research Program, National Institutes of Health; ¹⁵Center for Health Policy & Health Services Research, Henry Ford Health System; ¹⁶School of Public Health, University of Illinois at Chicago; ¹⁷Cardiology Section, Department of Medicine, Veterans Administration Boston Healthcare System and Harvard Medical School: ¹⁸Division of Preventive Medicine. University of Alabama at Birmingham; ¹⁹Institute of Genomic Medicine, Columbia University Medical Center; ²⁰Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University; ²¹Center for Precision Medicine, Marshfield Clinic; ²²Cherokee Health Systems; ²³Department of Genetics, University of Alabama at Birmingham; ²⁴Department of Psychiatry and Center for Genomic Medicine, Massachusetts General Hospital; ²⁵Center for Biomedical Research, Tuskegee University; ²⁶Sage Bionetworks; ²⁷Broad Institute; Department of Pharmacology, Vanderbilt University Medical Center

*Address for correspondence:

Andrea* H. Ramirez, MD, MS

1215 21st Avenue South

Medical Center East, South Tower

Room / Suite 8210

Nashville, TN 37232-8148

Supplemental Figure 1. Participant counts by data type.

А



В



Count of Participants by Survey Modules

Count of participants by data types



D

С



Count of participants with EHR data by domain

Е



F



Supplemental Figure 1: Participant counts by data type. A: Participant count by data type including EHR, PPI surveys, and physical measurements. B: Participant count grouped by PPI survey module including "The Basics", "Lifestyle", "Overall Health", "Personal Medical History", "Health Care Access and Utilization", and "Family Medical History". C: Participant count by different physical measurements including waist circumference, hip circumference, heart rate, systolic and diastolic blood pressures, body mass index, body weight, body height, and wheelchair use. D: Counts of participants with EHR data by domain including observation, condition occurrence, measurement, drug exposure, procedure occurence and device exposure. E: Row counts by data source and domain table grouped by EHR data (gray) and PPI and PM (blue). F: Venn diagram showing overlap of participants with data from EHR, PPI Surveys Part 1 ("The Basics", "Lifestyle", "Overall Health"), PPI Surveys Part 2 ("Personal Medical History", "Health Care Access and Utilization"), and Program Physical Measurement data. By definition to be a participant included in the beta release, you must have answered PPI 1, therefore the zeros shown represent confirmation of this rule.

Supplemental Table 1. Codes used in ASCVD risk score calculation.

ischemic_heart_codes=['l20','l21','l22','l23','l24','l25','410','411','412','413','414']

stroke_codes=["430","431","432","434","434","435","I63.0","I63.1","I63.2","I63.3",

"I63.4","I63.5","I63.6","I63.8","I63.9","G45.9","I69.33","I69.34","I69.35"]

Diabetes ancestor codes: Type 2 diabetes mellitus 201826

Hypertension disease ancestor code: Hypertensive disorder 316866

HTN med treatment: Antihypertensive, Diuretics, Peripheral vasodilators, beta-blocking agents, calcium channel

blockers, agents acting on the renin-angiotensin

21600381,21601461,21601560,21601664,21601744,21601782

Supplemental Table 2. Individual Site EHR Medication Sequencing participants.

EHR site*	Number of participants with anti-diabetes sequences	Number of participants with antidepressant sequences
EHR site 111	74	61
EHR site 146	110	422
EHR site 199	545	580
EHR site 211	50	120
EHR site 234	200	411
EHR site 298	222	211
EHR site 323	35	<20

EHR site 352	354	245
EHR site 387	180	307
EHR site 394	110	371
EHR site 395	20	28
EHR site 473	206	467
EHR site 499	539	1028
EHR site 601	244	676
EHR site 609	35	62
EHR site 611	72	235
EHR site 638	103	48
EHR site 662	22	37
EHR site 671	96	152
EHR site 705	765	526
EHR site 712	726	670
EHR site 721	156	172

EHR site 772	99	344
EHR site 788	160	86
EHR site 803	212	63
EHR site 824	2032	4867
EHR site 842	31	86
EHR site 863	<20	<20
EHR site 868	179	250
EHR site 906	541	637
EHR site 916	<20	53
EHR site 950	688	963
EHR site 974	623	1591

*EHR site: individual health care EHR provider

ever_smoking_ppi	Ever Smoker	Never Smoker	Unknown	All
ehr_smoking				
No Codes and No EHR	34164	53833	9013	97010
No Codes and some EHR	29853	68025	2649	100527
One Code	6157	6157 1798		8271
Two Codes	15675	2020	640	18335
All	85849	125676	12618	224143

Supplemental Table 2. Overlap of participants in Smoking Exposure PheWAS.

Supplemental Table 3. Expanded PheWAS results for Ever smoking EHR and survey

data.

The "top" phenotypes are defined as the top 10 phenome-wide significant phenotypes sorted by effect size.

EHR Ever Smoker Oncologic PheWAS

Nonprotective

	phecode	description	cases	control	p_value	OR
	165.10	Cancer of bronchus; lung	547	95108	2.276786e-64	4.94 (4.11, 5.95)
	165.00	Cancer within the respiratory system	562	95108	5.500971e-66	4.94 (4.12, 5.92)
	189.21	Malignant neoplasm of bladder	339	94889	4.220036e-13	2.36 (1.87, 2.98)
	149.00	Cancer of larynx, pharynx, nasal cavities	242	95145	7.431440e-09	2.26 (1.71, 2.97)
	189.20	Cancer of bladder	364	94889	1.486141e-12	2.25 (1.8, 2.82)
	153.30	Malignant neoplasm of rectum, rectosigmoid jun	466	81540	2.245329e-14	2.17 (1.78, 2.65)
	155.10	Malignant neoplasm of liver, primary	189	90747	1.392056e-06	2.16 (1.58, 2.96)
	155.00	Cancer of liver and intrahepatic bile duct	229	90747	7.841085e-07	2.06 (1.54, 2.74)
	227.10	Benign neoplasm of adrenal gland	264	93746	2.975358e-06	1.87 (1.44, 2.43)
	184.00	Cancer of other female genital organs	500	53869	3.457014e-09	1.83 (1.5, 2.23)

Protective

OR	p_value	control	cases	description	phecode
0.51 (0.42, 0.62)	1.227894e-11	84356	869	Vascular hamartomas and non-neoplastic nevi	217.0
0.52 (0.43, 0.64)	1.175278e-10	84356	821	Nevus, non-neoplastic	217.1
0.53 (0.49, 0.58)	6.001888e-51	84356	5803	Benign neoplasm of skin	216.0
0.57 (0.47, 0.68)	9.085644e-10	92037	943	Hemangioma of skin and subcutaneous tissue	228.1
0.71 (0.62, 0.81)	5.674045e-07	92037	1536	Hemangioma and lymphangioma, any site	228.0

Overall

phecode	description	cases	control	p_value	OR
165.10	Cancer of bronchus; lung	547	95108	2.276786e-64	4.94 (4.11, 5.95)
165.00	Cancer within the respiratory system	562	95108	5.500971e-66	4.94 (4.12, 5.92)
189.21	Malignant neoplasm of bladder	339	94889	4.220036e-13	2.36 (1.87, 2.98)
149.00	Cancer of larynx, pharynx, nasal cavities	242	95145	7.431440e-09	2.26 (1.71, 2.97)
189.20	Cancer of bladder	364	94889	1.486141e-12	2.25 (1.8, 2.82)
153.30	Malignant neoplasm of rectum, rectosigmoid jun	466	81540	2.245329e-14	2.17 (1.78, 2.65)
155.10	Malignant neoplasm of liver, primary	189	90747	1.392056e-06	2.16 (1.58, 2.96)
155.00	Cancer of liver and intrahepatic bile duct	229	90747	7.841085e-07	2.06 (1.54, 2.74)
217.00	Vascular hamartomas and non-neoplastic nevi	869	84356	1.227894e-11	0.51 (0.42, 0.62)
217.10	Nevus, non-neoplastic	821	84356	1.175278e-10	0.52 (0.43, 0.64)

Survey Current Smoker Oncologic PheWAS

Nonprotective

phecode	description	cases	control	p_value	OR
165.10	Cancer of bronchus; lung	268	77672	1.968977e-19	3.52 (2.68, 4.62)
165.00	Cancer within the respiratory system	275	77672	9.589970e-19	3.38 (2.58, 4.44)
189.21	Malignant neoplasm of bladder	189	77447	4.125790e-07	2.52 (1.76, 3.6)

Protective

phecode	description	cases	control	p_value	OR
217.10	Nevus, non-neoplastic	582	69636	6.238387e-14	0.24 (0.17, 0.35)
217.00	Vascular hamartomas and non-neoplastic nevi	623	69636	1.154638e-14	0.25 (0.18, 0.36)
228.10	Hemangioma of skin and subcutaneous tissue	654	75337	3.781155e-12	0.26 (0.17, 0.38)
216.00	Benign neoplasm of skin	4237	69636	5.821750e-87	0.27 (0.23, 0.3)
173.00	Neoplasm of uncertain behavior of skin	1377	72648	1.109613e-24	0.34 (0.27, 0.42)
204.40	Multiple myeloma	204	76060	2.475480e-05	0.35 (0.22, 0.57)
172.21	Basal cell carcinoma	738	72648	1.053635e-10	0.36 (0.26, 0.49)
204.00	Leukemia	498	76060	8.905774e-11	0.36 (0.27, 0.49)
228.00	Hemangioma and lymphangioma, any site	1077	75337	2.464672e-16	0.36 (0.28, 0.46)
172.10	Melanomas of skin, dx or hx	485	72648	3.876019e-08	0.37 (0.26, 0.53)

Overall

phecode	description	cases	control	p_value	OR
217.10	Nevus, non-neoplastic	582	69636	6.238387e-14	0.24 (0.17, 0.35)
217.00	Vascular hamartomas and non-neoplastic nevi	623	69636	1.154638e-14	0.25 (0.18, 0.36)
228.10	Hemangioma of skin and subcutaneous tissue	654	75337	3.781155e-12	0.26 (0.17, 0.38)
216.00	Benign neoplasm of skin	4237	69636	5.821750e-87	0.27 (0.23, 0.3)
165.10	Cancer of bronchus; lung	268	77672	1.968977e-19	3.52 (2.68, 4.62)
165.00	Cancer within the respiratory system	275	77672	9.589970e-19	3.38 (2.58, 4.44)
173.00	Neoplasm of uncertain behavior of skin	1377	72648	1.109613e-24	0.34 (0.27, 0.42)
204.40	Multiple myeloma	204	76060	2.475480e-05	0.35 (0.22, 0.57)
172.21	Basal cell carcinoma	738	72648	1.053635e-10	0.36 (0.26, 0.49)
204.00	Leukemia	498	76060	8.905774e-11	0.36 (0.27, 0.49)

Survey Ever Smoker Oncologic PheWAS

Nonprotective

phecode	description	cases	control	p_value	OR
165.10	Cancer of bronchus; lung	592	100501	3.550585e-34	3.19 (2.65, 3.84)
165.00	Cancer within the respiratory system	607	100501	1.977280e-34	3.15 (2.62, 3.78)
180.10	Cervical cancer	247	50045	2.105232e-07	2.0 (1.54, 2.59)
189.21	Malignant neoplasm of bladder	372	100275	2.547259e-07	1.76 (1.42, 2.18)
189.20	Cancer of bladder	402	100275	6.152779e-07	1.69 (1.37, 2.08)

Protective

p	hecode	description	cases	control	p_value	OR
	217.0	Vascular hamartomas and non-neoplastic nevi	895	89274	2.323566e-15	0.55 (0.48, 0.64)
	217.1	Nevus, non-neoplastic	847	89274	6.477657e-14	0.57 (0.49, 0.66)
	216.0	Benign neoplasm of skin	6116	89274	1.483150e-51	0.62 (0.58, 0.66)
	228.1	Hemangioma of skin and subcutaneous tissue	1003	97279	2.766770e-10	0.65 (0.57, 0.74)
	185.0	Cancer of prostate	1530	27165	1.380273e-09	0.69 (0.61, 0.78)
	228.0	Hemangioma and lymphangioma, any site	1626	97279	1.232647e-11	0.69 (0.62, 0.77)
	196.0	Radiotherapy	4466	84432	4.800319e-23	0.7 (0.65, 0.75)
	197.0	Chemotherapy	6114	84432	2.095024e-24	0.73 (0.68, 0.77)
	173.0	Neoplasm of uncertain behavior of skin	2101	93050	4.468407e-11	0.73 (0.66, 0.8)
	218.1	Uterine leiomyoma	3080	53707	4.420974e-12	0.74 (0.68, 0.81)

Overall

p	hecode	description	cases	control	p_value	OR
	165.10	Cancer of bronchus; lung	592	100501	3.550585e-34	3.19 (2.65, 3.84)
	165.00	Cancer within the respiratory system	607	100501	1.977280e-34	3.15 (2.62, 3.78)
	180.10	Cervical cancer	247	50045	2.105232e-07	2.0 (1.54, 2.59)
	217.00	Vascular hamartomas and non-neoplastic nevi	895	89274	2.323566e-15	0.55 (0.48, 0.64)
	217.10	Nevus, non-neoplastic	847	89274	6.477657e-14	0.57 (0.49, 0.66)
	189.21	Malignant neoplasm of bladder	372	100275	2.547259e-07	1.76 (1.42, 2.18)
	189.20	Cancer of bladder	402	100275	6.152779e-07	1.69 (1.37, 2.08)
	216.00	Benign neoplasm of skin	6116	89274	1.483150e-51	0.62 (0.58, 0.66)
	228.10	Hemangioma of skin and subcutaneous tissue	1003	97279	2.766770e-10	0.65 (0.57, 0.74)
	185.00	Cancer of prostate	1530	27165	1.380273e-09	0.69 (0.61, 0.78)

Supplemental Table 4. ASCVD risk score demographic distributions

	All participants	Participants	ASCVD scores	ASCVD scores
	(n=229255)	with any EHR	(n=26007)	within a year of
		(n= 118332)		enrollment
				(n=6225)
Gender				
Male	85,645	42,867	8,655 (33.28%)	2,127 (34.17%)
	(37.36%)	(63.27%)		

Female	140,818	74,867	17,352 (66.72%)	4,098 (65.83%)
	(61.42%)	(35.52%)		
prefer not	2,789 (1.21%)	1,435 (1.21%)	0 (0%)	0 (0%)
to				
answer				
Race				
White	120,760	61,348	15,743 (60.53%)	3,344 (53.71%)
	(52.67%)	(51.84%)		
Black	46,679	24,450	5,491 (21.13%)	1,576 (25.31%)
	(20.36%)	(20.66%)		
Hispanic	42,736	23,355	3,198 (12.30%)	885 (14.22%)
	(18.64%)	(19.74%)		
Asian	7,602 (3.32%)	3,309 (2.80%)	546 (2.10%)	144 (2.31%)
More	4,134 (1.80%)	2,023 (1.70%)	304 (1.17%)	87 (1.40%)
than one				
populatio				
n				
Another	1,705 (0.74%)	894 (0.76%)	139 (0.53%)	46 (0.74%)
single				
populatio				
n				
None of	2,401 (1.04%)	1,254 (1.06%)	250 (0.96%)	54 (0.87%)
these				

Prefer	1,654 (0.72%)	873 (0.74%)	155 (0.53%)	47 (0.76%)
not to				
answer				
Skip	1,584 (0.70%)	826 (0.70%)	181 (0.7%)	42 (0.67%)

Supplemental Table 5. Approximate compute cost on Researcher Workbench for individual analyses, in dollars.

Analysis	Development cost	Single run cost	Total cost
Descriptive metrics	28.35	3.48	31.83
Medication sequencing	28.15	6.39	34.54
Smoking exposure PheWAS	7.00	4.20	11.20
ASCVD score calculation	11.71	7.20	18.91
Total	75.21	21.27	96.48

* Access to the Researcher Workbench and data are free. Compute and storage accrue usage cost. The Researcher Workbench uses Google Compute Engine (GCE) for computational resources in the cloud and Google Cloud Storage (GCS) for storage in the cloud. Jupyter Notebooks are loaded in a GCE Virtual machine, which is ephemeral. During this project, the

hourly rate of the default n1-highmem-4 machine was \$0.27 per hour, including the cost for dataproc clusters. Notebooks not in active use are "paused" accruing cost of under \$0.10 per day and shut down to zero cost after two weeks of inactivity. The storage "bucket" associated with Notebooks within a workspace costs \$0.026 per GB per month.

Data Availability Links: The All of Us Researcher Workbench

Medication sequences for Type 2 diabetes and depression comparison by race:

https://workbench.researchallofus.org/workspaces/aou-rw-dd7cff0e/medicationspathwaysequen cesbyracephase1/notebooks Cardiovascular risk score: https://workbench.researchallofus.org/workspaces/aou-rw-a8fc912d/duplicateofframinghamahar iskscore/notebooks PheWAS Smoking: https://workbench.researchallofus.org/workspaces/aou-rw-d59956e4/jamaphewasfinalreview05 212020/data